LAB MONTHLY SUMMARY

Lab Name MORRIS MATHIAS HOSPITAL **Lab No** 0399

Month June **Year** 2020

Constituent Group Chemistry I

Date of Result Entered : 19/06/2020

Date of Report Published : 08/08/2020

Sl.No	Analyte	Method / Principle Name	Analyzer Name	No of Participants	DV	Participants CV	Participants SD	Your Value	SDI	U
1	GLUCOSE	HEXOKINASE	Beckman AU480/680/5800/DXC700AU	121	78.16	6.84	5.35	77 mg/dl	-0.22	0.97
2	UREA	UREASE UV / GLDH	Beckman AU480/680/5800/DXC700AU	148	49.86	4.80	2.39	52 mg/dl	0.89	0.39
3	CREATININE	JAFFE RATE-BLANKED &COMPENSATED/Alkaline Picrate	Beckman AU480/680/5800/DXC700AU	109	3.65	6.81	0.25	3.5 mg/dl	-0.60	0.05
4	T.BILIRUBIN	DIAZONIUM SALT (Colorimetric) /JENDRASSIK	Beckman AU480/680/5800/DXC700AU	134	5.75	4.44	0.26	5.8 mg/dl	0.20	0.04
5	T-PROTEIN	BIURET - colorimetric	Beckman AU480/680/5800/DXC700AU	149	4.30	3.77	0.16	4.3 g/dl	0.00	0.03
6	ALBUMIN	BCG - colorimetric	Beckman AU480/680/5800/DXC700AU	146	2.66	3.98	0.11	2.7 g/dl	0.38	0.02
7	CALCIUM	ARSENAZO III	Beckman AU480/680/5800/DXC700AU	120	10.21	3.58	0.37	10.2 mg/dl	-0.03	0.07
8	PHOSPHORUS	Molybdate UV/ Phosphomolybdate complex	Beckman AU480/680/5800/DXC700AU	105	5.20	5.96	0.31	5.2 mg/dl	0.00	0.06
9	URIC ACID	ENZYMATIC / URICASE Colorimetric	Beckman AU480/680/5800/DXC700AU	142	3.80	4.08	0.16	3.9 mg/dl	0.65	0.03
10	CHOLESTEROL	CHOD-PAP	Beckman AU480/680/5800/DXC700AU	148	87.68	5.99	5.25	85 mg/dl	-0.51	0.86
11	TRIGLYCERIDE	GPO-PAP / Enzymatic Colorimetric / End Point	Beckman AU480/680/5800/DXC700AU	146	81.18	7.25	5.88	89 mg/dl	1.33	0.97
12	HDL CHO	DIRECT METHOD / Enzymatic colorimetric	Beckman AU480/680/5800/DXC700AU	125	21.54	8.89	1.92	24 mg/dl	1.28	0.34
13	SODIUM	ISE - Indirect	Any Analyser	947	117.55	4.80	5.65	113 mmol/L	-0.81	0.37
14	POTASSIUM	ISE - Indirect	Any Analyser	963	5.25	6.49	0.34	5.3 mmol/L	0.15	0.02
15	AST	UV-Kinetic without PLP (P-5-P)	Beckman AU480/680/5800/DXC700AU	84	112.82	10.55	11.91	121 U/L	0.69	2.60
16	ALT	UV-Kinetic without PLP (P-5-P)	Beckman AU480/680/5800/DXC700AU	84	291.45	16.96	49.43	313 U/L	0.44	10.79
17	ALP	PNP AMP KINETIC	Beckman AU480/680/5800/DXC700AU	130	168.75	15.24	25.71	182 U/L	0.52	4.51
18	AMYLASE	CNPG3	Any Analyser	641	60.86	21.18	12.89	53 U/L	-0.61	1.02
19	CPK	NAC ACTIVATED	Beckman AU480/680/5800/DXC700AU	44	33.49	17.95	6.01	33 U/L	-0.08	1.81
20	MAGNESIUM	XYLIDYL BLUE	Beckman AU480/680/5800/DXC700AU	41	3.49	7.71	0.27	3.7 mg/dl	0.78	0.08

SDI Range	Interpretation
Within -1.0 to +1.0	Excellent.
Between ±1.0 to ±2.0	Good.
Between ±2.0 to ±3.0	Accept with caution. Warning Signal.
Beyond ±3.0	Unacceptable performance. Action Signal.

Homogeneity and Stability of the sample is passed.

Data in CMC EQAS reports is confidential

Contact details:

Email:clinqc@cmcvellore.ac.in

Contact Number: 0416-2283102

ONTHLY SUMMARY

Lab Name	**MORRIS MATHIAS HOSPITAL**	**Lab No**	**0399**
Month	**June**	**Year**	**2020**
Constituent Group	**HbA1c**		

Date of Result Entered : 19/06/2020

Date of Report Published : 08/08/2020

Sl.No	Analyte	Method / Principle Name	Analyzer Name	No of Participants	DV	Participants CV	Participants SD	Your Value	SDI	U
1	HbA1c	TURBIDIMETRIC INHIBITION IMMUNO ASSAY	Beckman AU480/680/5800/DXC700AU	20	7.33	9.46	0.69	7 %	-0.48	0.31

SDI Range	Interpretation
Within -1.0 to +1.0	Excellent.
Between ±1.0 to ±2.0	Good.
Between ±2.0 to ±3.0	Accept with caution. Warning Signal.
Beyond ±3.0	Unacceptable performance. Action Signal.

Homogeneity and Stability of the sample is passed.

Data in CMC EQAS reports is confidential

Contact details:
Email:clinqc@cmcvellore.ac.in
Contact Number: 0416-2283102

Pamela Christudoss

Dr. Pamela Christudoss
CMC EQAS Co-Ordinator
Christian Medical College, Vellore

********* End of Report ********

LAB MONTHLY SUMMARY

Lab Name MORRIS MATHIAS HOSPITAL **Lab No** 0399

Month July **Year** 2020

Constituent Group Chemistry I

Date of Result Entered : 20/07/2020

Date of Report Published : 14/08/2020

Sl.No	Analyte	Method / Principle Name	Analyzer Name	No of Participants	DV	Participants CV	Participants SD	Your Value	SDI	U
1	GLUCOSE	HEXOKINASE	Beckman AU480/680/5800/DXC700AU	114	410.46	4.71	19.32	410 mg/dl	-0.02	3.62
2	UREA	UREASE UV / GLDH	Beckman AU480/680/5800/DXC700AU	157	94.87	5.08	4.82	97 mg/dl	0.44	0.77
3	CREATININE	JAFFE RATE-BLANKED &COMPENSATED/Alkaline Picrate	Beckman AU480/680/5800/DXC700AU	110	0.89	16.25	0.14	0.9 mg/dl	0.07	0.03
4	T.BILIRUBIN	DIAZONIUM SALT (Colorimetric) /JENDRASSIK	Beckman AU480/680/5800/DXC700AU	139	4.30	3.95	0.17	4.3 mg/dl	0.00	0.03
5	T-PROTEIN	BIURET - colorimetric	Beckman AU480/680/5800/DXC700AU	153	4.84	5.27	0.26	5 g/dl	0.63	0.04
6	ALBUMIN	BCG - colorimetric	Beckman AU480/680/5800/DXC700AU	148	2.97	4.37	0.13	3 g/dl	0.23	0.02
7	CALCIUM	ARSENAZO III	Beckman AU480/680/5800/DXC700AU	119	11.38	2.90	0.33	11.7 mg/dl	0.97	0.06
8	PHOSPHORUS	Molybdate UV/ Phosphomolybdate complex	Beckman AU480/680/5800/DXC700AU	107	3.02	6.12	0.18	2.8 mg/dl	-1.19	0.04
9	URIC ACID	ENZYMATIC / URICASE Colorimetric	Beckman AU480/680/5800/DXC700AU	150	7.28	4.08	0.30	7.4 mg/dl	0.40	0.05
10	CHOLESTEROL	CHOD-PAP	Beckman AU480/680/5800/DXC700AU	148	101.27	5.83	5.91	97 mg/dl	-0.72	0.97
11	TRIGLYCERIDE	GPO-PAP / Enzymatic Colorimetric / End Point	Beckman AU480/680/5800/DXC700AU	150	225.22	6.39	14.39	235 mg/dl	0.68	2.35
12	HDL CHO	DIRECT METHOD / Enzymatic colorimetric	Beckman AU480/680/5800/DXC700AU	122	23.24	6.72	1.56	25 mg/dl	1.13	0.28
13	SODIUM	ISE - Indirect	Any Analyser	928	140.81	3.28	4.62	143 mmol/L	0.47	0.30
14	POTASSIUM	ISE - Indirect	Any Analyser	930	3.02	5.95	0.18	3 mmol/L	-0.11	0.01
15	AST	UV-Kinetic without PLP (P-5-P)	Beckman AU480/680/5800/DXC700AU	86	226.12	11.40	25.77	251 U/L	0.97	5.56
16	ALT	UV-Kinetic without PLP (P-5-P)	Beckman AU480/680/5800/DXC700AU	83	134.65	15.66	21.09	151 U/L	0.78	4.63
17	ALP	PNP AMP KINETIC	Beckman AU480/680/5800/DXC700AU	143	65.26	13.51	8.82	71 U/L	0.65	1.47
18	AMYLASE	CNPG3	Any Analyser	630	39.27	23.01	9.04	36 U/L	-0.36	0.72
19	MAGNESIUM	XYLIDYL BLUE	Beckman AU480/680/5800/DXC700AU	43	1.65	8.61	0.14	1.7 mg/dl	0.35	0.04

SDI Range	Interpretation
Within -1.0 to +1.0	Excellent.
Between ±1.0 to ±2.0	Good.
Between ±2.0 to ±3.0	Accept with caution. Warning Signal.
Beyond ±3.0	Unacceptable performance. Action Signal.

Homogeneity and Stability of the sample is passed.

Data in CMC EQAS reports is confidential

Contact details:
Email:clinqc@cmcvellore.ac.in
Contact Number: 0416-2283102

LAB MONTHLY SUMMARY

Lab Name MORRIS MATHIAS HOSPITAL **Lab No** 0399

Month July **Year** 2020

Constituent Group HbA1c

Date of Result Entered : 20/07/2020

Date of Report Published : 14/08/2020

Sl.No	Analyte	Method / Principle Name	Analyzer Name	No of Participants	DV	Participants CV	Participants SD	Your Value	SDI	U
1	HbA1c	TURBIDIMETRIC INHIBITION IMMUNO ASSAY	Beckman AU480/680/5800/DXC700AU	18	7.66	10.85	0.83	8.2 %	0.65	0.39

SDI Range	Interpretation
Within -1.0 to +1.0	Excellent.
Between ±1.0 to ±2.0	Good.
Between ±2.0 to ±3.0	Accept with caution. Warning Signal.
Beyond ±3.0	Unacceptable performance. Action Signal.

Homogeneity and Stability of the sample is passed.

Data in CMC EQAS reports is confidential

Contact details:
Email:clinqc@cmcvellore.ac.in
Contact Number: 0416-2283102

Pamela Christudoss

Dr. Pamela Christudoss
CMC EQAS Co-Ordinator
Christian Medical College, Vellore

********* End of Report ********

LAB MONTHLY SUMMARY

Lab Name: MORRIS MATHIAS HOSPITAL | Lab No: 0399

Month: May | Year: 2020

Constituent Group: Chemistry I

Date of Result Entered : 19/06/2020

Date of Report Published : 04/08/2020

Sl.No	Analyte	Method / Principle Name	Analyzer Name	No of Participants	DV	Participants CV	Participants SD	Your Value	SDI	U
1	GLUCOSE	HEXOKINASE	Beckman AU480/680/5800/DXC700AU	116	259.76	5.46	14.19	256 mg/dl	-0.26	2.63
2	UREA	UREASE UV / GLDH	Beckman AU480/680/5800/DXC700AU	142	121.25	4.76	5.77	120 mg/dl	-0.22	0.97
3	CREATININE	JAFFE RATE-BLANKED &COMPENSATED/Alkaline Picrate	Beckman AU480/680/5800/DXC700AU	106	6.87	6.62	0.46	6.4 mg/dl	-1.03	0.09
4	T.BILIRUBIN	DIAZONIUM SALT (Colorimetric) /JENDRASSIK	Beckman AU480/680/5800/DXC700AU	127	2.16	4.08	0.09	2.1 mg/dl	-0.68	0.02
5	T-PROTEIN	BIURET - colorimetric	Beckman AU480/680/5800/DXC700AU	139	4.95	4.24	0.21	4.9 g/dl	-0.24	0.04
6	ALBUMIN	BCG - colorimetric	Beckman AU480/680/5800/DXC700AU	140	3.01	4.42	0.13	3 g/dl	-0.08	0.02
7	CALCIUM	ARSENAZO III	Beckman AU480/680/5800/DXC700AU	111	9.04	3.54	0.32	8.8 mg/dl	-0.75	0.06
8	PHOSPHORUS	Molybdate UV/ Phosphomolybdate complex	Beckman AU480/680/5800/DXC700AU	100	3.29	8.35	0.28	3.2 mg/dl	-0.33	0.05
9	URIC ACID	ENZYMATIC / URICASE Colorimetric	Beckman AU480/680/5800/DXC700AU	136	9.00	3.73	0.34	9.1 mg/dl	0.30	0.06
10	CHOLESTEROL	CHOD-PAP	Beckman AU480/680/5800/DXC700AU	139	109.12	5.79	6.32	106 mg/dl	-0.49	1.07
11	TRIGLYCERIDE	GPO-PAP / Enzymatic Colorimetric / End Point	Beckman AU480/680/5800/DXC700AU	139	163.40	5.86	9.58	171 mg/dl	0.79	1.62
12	HDL CHO	DIRECT METHOD / Enzymatic colorimetric	Beckman AU480/680/5800/DXC700AU	121	24.05	7.05	1.69	25 mg/dl	0.56	0.31
13	SODIUM	ISE - Indirect	Any Analyser	928	135.13	3.38	4.57	133 mmol/L	-0.47	0.30
14	POTASSIUM	ISE - Indirect	Any Analyser	922	3.45	6.32	0.22	3.4 mmol/L	-0.23	0.01
15	AST	UV-Kinetic without PLP (P-5-P)	Beckman AU480/680/5800/DXC700AU	79	59.73	12.21	7.29	63 U/L	0.45	1.64
16	ALT	UV-Kinetic without PLP (P-5-P)	Beckman AU480/680/5800/DXC700AU	76	91.97	14.77	13.58	96 U/L	0.30	3.12
17	ALP	PNP AMP KINETIC	Beckman AU480/680/5800/DXC700AU	128	44.20	16.34	7.22	47 U/L	0.39	1.28
18	AMYLASE	CNPG3	Any Analyser	634	79.80	21.18	16.90	69 U/L	-0.64	1.34
19	MAGNESIUM	XYLIDYL BLUE	Beckman AU480/680/5800/DXC700AU	40	2.35	7.50	0.18	2.3 mg/dl	-0.28	0.06

SDI Range	Interpretation
Within -1.0 to +1.0	Excellent.
Between ±1.0 to ±2.0	Good.
Between ±2.0 to ±3.0	Accept with caution. Warning Signal.
Beyond ±3.0	Unacceptable performance. Action Signal.

Homogeneity and Stability of the sample is passed.

Data in CMC EQAS reports is confidential

Contact details:
Email:clinqc@cmcvellore.ac.in
Contact Number: 0416-2283102

LAB MONTHLY SUMMARY

Lab Name	**MORRIS MATHIAS HOSPITAL**	**Lab No**	**0399**
Month	**May**	**Year**	**2020**
Constituent Group	**HbA1c**		

Date of Result Entered : 19/06/2020

Date of Report Published : 04/08/2020

Sl.No	Analyte	Method / Principle Name	Analyzer Name	No of Participants	DV	Participants CV	Participants SD	Your Value	SDI	U
1	HbA1c	TURBIDIMETRIC INHIBITION IMMUNO ASSAY	Beckman AU480/680/5800/DXC700AU	20	5.48	14.99	0.82	4.8 %	-0.83	0.37

SDI Range	Interpretation
Within -1.0 to +1.0	Excellent.
Between ±1.0 to ±2.0	Good.
Between ±2.0 to ±3.0	Accept with caution. Warning Signal.
Beyond ±3.0	Unacceptable performance. Action Signal.

Homogeneity and Stability of the sample is passed.

Data in CMC EQAS reports is confidential

Contact details:
Email:clinqc@cmcvellore.ac.in
Contact Number: 0416-2283102

Pamela Christudoss

Dr. Pamela Christudoss
CMC EQAS Co-Ordinator
Christian Medical College, Vellore

********* End of Report ********

LAB MONTHLY SUMMARY

Lab Name	**MORRIS MATHIAS HOSPITAL**	**Lab No**	**0399**
Month	**May**	**Year**	**2020**
Constituent Group	**Chemistry I**		

Date of Result Entered : 19/06/2020

Date of Report Published : 04/08/2020

Sl.No	Analyte	Method / Principle Name	Analyzer Name	No of Participants	Participants DV	Participants CV	Participants SD	Your Value	SDI	U
1	GLUCOSE	HEXOKINASE	Beckman AU480/680/5800/DXC700AU	116	259.76	5.46	14.19	256 mg/dl	-0.26	2.63
2	UREA	UREASE UV / GLDH	Beckman AU480/680/5800/DXC700AU	142	121.25	4.76	5.77	120 mg/dl	-0.22	0.97
3	CREATININE	JAFFE RATE BLANKED &COMPENSATED/Alkaline Picrate	Beckman AU480/680/5800/DXC700AU	106	6.87	6.62	0.46	6.4 mg/dl	-1.03	0.09
4	T.BILIRUBIN	DIAZONIUM SALT (Colorimetric) /JENDRASSIK	Beckman AU480/680/5800/DXC700AU	127	2.16	4.08	0.09	2.1 mg/dl	-0.68	0.02
5	T-PROTEIN	BIURET - colorimetric	Beckman AU480/680/5800/DXC700AU	139	4.95	4.24	0.21	4.9 g/dl	-0.24	0.04
6	ALBUMIN	BCG - colorimetric	Beckman AU480/680/5800/DXC700AU	140	3.01	4.42	0.13	3 g/dl	-0.08	0.02
7	CALCIUM	ARSENAZO III	Beckman AU480/680/5800/DXC700AU	111	9.04	3.54	0.32	8.8 mg/dl	-0.75	0.06
8	PHOSPHORUS	Molybdate UV/ Phosphomolybdate complex	Beckman AU480/680/5800/DXC700AU	100	3.29	8.35	0.28	3.2 mg/dl	-0.33	0.05
9	URIC ACID	ENZYMATIC / URICASE Colorimetric	Beckman AU480/680/5800/DXC700AU	136	9.00	3.73	0.34	9.1 mg/dl	0.30	0.06
10	CHOLESTEROL	CHOD-PAP	Beckman AU480/680/5800/DXC700AU	139	109.12	5.79	6.32	106 mg/dl	-0.49	1.07
11	TRIGLYCERIDE	GPO-PAP / Enzymatic Colorimetric / End Point	Beckman AU480/680/5800/DXC700AU	139	163.40	5.86	9.58	171 mg/dl	0.79	1.62
12	HDL CHO	DIRECT METHOD / Enzymatic colorimetric	Beckman AU480/680/5800/DXC700AU	121	24.05	7.05	1.69	25 mg/dl	0.56	0.31
13	SODIUM	ISE - Indirect	Any Analyser	928	135.13	3.38	4.57	133 mmol/L	-0.47	0.30
14	POTASSIUM	ISE - Indirect	Any Analyser	922	3.45	6.32	0.22	3.4 mmol/L	-0.23	0.01
15	AST	UV-Kinetic without PLP (P-5-P)	Beckman AU480/680/5800/DXC700AU	79	59.73	12.21	7.29	63 U/L	0.45	1.64
16	ALT	UV-Kinetic without PLP (P-5-P)	Beckman AU480/680/5800/DXC700AU	76	91.97	14.77	13.58	96 U/L	0.30	3.12
17	ALP	PNP AMP KINETIC	Beckman AU480/680/5800/DXC700AU	128	44.20	16.34	7.22	47 U/L	0.39	1.28
18	AMYLASE	CNPG3	Any Analyser	634	79.80	21.18	16.90	69 U/L	-0.64	1.34
19	MAGNESIUM	XYLIDYL BLUE	Beckman AU480/680/5800/DXC700AU	40	2.35	7.50	0.18	2.3 mg/dl	-0.28	0.06

SDI Range	Interpretation
Within -1.0 to +1.0	Excellent.
Between ±1.0 to ±2.0	Good.
Between ±2.0 to ±3.0	Accept with caution. Warning Signal.
Beyond ±3.0	Unacceptable performance. Action Signal.

Homogeneity and Stability of the sample is passed.

Data in CMC EQAS reports is confidential

Contact details:

Email:clinqc@cmcvellore.ac.in

Contact Number: 0416-2283102

CMCVIROEQAS
(Under the aegis of Indian Association of Medical Microbiologists)
PT Unit, Department of Clinical Virology, Christian Medical College,
Vellore-632004, Tamil Nadu
Email: viroeqas@cmcvellore.ac.in Phone: 0416-2283455

CMCVIROEQAS SEROLOGY CONSOLIDATED EVALUATION REPORT 2019

PANEL : BLOOD BORNE VIRAL SCREEN (BBVS)

CMCVIROEQAS ID.: V0461 **Report Dispatching Date:** 20-03-2020

Cumulative Report of your laboratory for the year 2019

	HIV-Ab/Ag	HBsAg	HCV-Ab	Total
Number of Specimens	12			
Number of tests performed	12	12	12	36
Number of tests reported as not examined	0	0	0	0
Number of specimens not used for analysis	0	0	0	0

Your cumulative score for the specimens you reported : **72** out of the possible total of 72

Total Number of participants for BBVS : 524

Number of participants participated in 2 or more surveys : 473

CMCVIROEQAS
(Under the aegis of Indian Association of Medical Microbiologists)
PT Unit, Department of Clinical Virology, Christian Medical College,
Vellore-632004, Tamil Nadu
Email: viroeqas@cmcvellore.ac.in Phone: 0416-2283455



Standard Deviation Index (SDI)

Performance of the participating Laboratories	HIV Ag/Ab	HBsAg	HCV-Ab
Mean of All Laboratories	23.95	23.91	23.94
Standard Deviation	0.31	0.51	0.35
Your Laboratory SDI	**0.2**	**0.2**	**0.2**
Performance grade	**GOOD**	**GOOD**	**GOOD**

CMCVIROEQAS
(Under the aegis of Indian Association of Medical Microbiologists)
PT Unit, Department of Clinical Virology, Christian Medical College,
Vellore-632004, Tamil Nadu
Email: viroeqas@cmcvellore.ac.in Phone: 0416-2283455

Scoring System

Qualitative Results	Score
Concordant Result	2
Intermediate/Indeterminate	1
Discordant Result	0

Performance Score based on Standard Deviation Index (SDI)

Performance of the participating Laboratories	SDI
Good	± 2.0
Average	± 2.0 – 3.0
Poor	± >3.0

Comments:

Participants were scored based on qualitative result.

Standard Deviation Index (SDI):

Standard deviation index is used to analyze your laboratories performance relative to the other participating laboratories. The SDI is calculated for each parameter or marker separately using the formula

SDI = (Your result – interlaboratory mean)/interlaboratory standard deviation

CMCVIROEQAS
(Under the aegis of Indian Association of Medical Microbiologists)
PT Unit, Department of Clinical Virology, Christian Medical College,
Vellore-632004, Tamil Nadu
Email: viroeqas@cmcvellore.ac.in Phone: 0416-2283455

Enquiries: For queries please contact The CMCVIROEQAS coordinator at the email **viroeqas@cmcvellore.ac.in**

For all communications please use your **CMCVIROEQAS ID.**

Name of CMCVIROEQAS Coordinator **Signature**

Dr. Rajesh Kannangai

Department of Clinical Virology

Date: 20-03-2020

Report authorized by: CMCVIROEQAS Coordinator

END OF REPORT

Roche
Cobas e411

m- Edia

CMCVIROEQAS

(Under the aegis of Indian Association of Medical Microbiologists)

PT Unit, Department of Clinical Virology, Christian Medical College,
Vellore-632004, Tamil Nadu

Email: viroeqas@cmcvellore.ac.in Phone: 0416-2283455

9th SEROLOGY CMCVIROEQAS EVALUATION REPORT

PANEL: BBVS

(NABL)

CMCVIROEQAS ID. V0461 **Result Receiving Date:** 20/11/2019

Distribution No: 0319

Specimen #	Intended Result			Your Result		
	HIV	HBsAg	HCV	HIV	HBsAg	HCV
S0131909	Positive	Positive	Positive	POSITIVE	POSITIVE	POSITIVE
S0131910	Negative	Negative	Negative	NEGATIVE	NEGATIVE	NEGATIVE
S0131911	Negative	Negative	Negative	NEGATIVE	NEGATIVE	NEGATIVE
S0131912	Negative	Negative	Negative	NEGATIVE	NEGATIVE	NEGATIVE
Your Score				**8/8 (100%)**	**8/8 (100%)**	**8/8 (100%)**

Cumulative Report of this cycle:

Total Number of specimens you received : 4

Number of markers reported as not examined : 0

Specimen # not used for analysis : 0

Number of Specimens Reported Late for analysis : 0

Your cumulative score for the specimens you reported: 24 out of the possible total of 24

CMCVIROEQAS
(Under the aegis of Indian Association of Medical Microbiologists)
PT Unit, Department of Clinical Virology, Christian Medical College,
Vellore-632004, Tamil Nadu
Email: viroeqas@cmcvellore.ac.in Phone: 0416-2283455

Total Number of participants for BBVS : 524

Total Number of Participants who turned in their results : 467

Participants who reported all analyzed specimens accurately

Marker	Number of Participants	Percentage of Participants with concordant result for all analyzed specimens
HIV	465	98.7
HBsAg	467	98.5
HCV-Ab	466	98.7

Performance Graph



CMCVIROEQAS
(Under the aegis of Indian Association of Medical Microbiologists)
PT Unit, Department of Clinical Virology, Christian Medical College,
Vellore-632004, Tamil Nadu
Email: viroeqas@cmcvellore.ac.in Phone: 0416-2283455





CMCVIROEQAS
(Under the aegis of Indian Association of Medical Microbiologists)
PT Unit, Department of Clinical Virology, Christian Medical College,
Vellore-632004, Tamil Nadu
Email: viroeqas@cmcvellore.ac.in Phone: 0416-2283455



Comments:

Participants are scored based on qualitative result.

Assigned Value:

Assigned value is determined using multiple assays/multiple testing of the same analyte.

The proficiency testing material is a pooled lyophilized plasma sample prepared by following institutional proficiency testing standard operating protocol (PT-SOP) by trained staff. None of the work related to testing, preparation and packaging of sample is subcontracted. The homogeneity of the PT material is determined using multiple testing of multiple aliquots. The stability of the testing material is determined by assessing the reactivity of the specimen till the closing date.

CMCVIROEQAS
(Under the aegis of Indian Association of Medical Microbiologists)
PT Unit, Department of Clinical Virology, Christian Medical College,
Vellore-632004, Tamil Nadu
Email: viroeqas@cmcvellore.ac.in Phone: 0416-2283455

Scoring System

Qualitative Results	Score
Concordant Result	2
Intermediate/Indeterminate	1
Discordant Result	0

Enquiries: For queries please contact CMCVIROEQAS coordinator at the email **viroeqas@cmcvellore.ac.in**

For all communications please use your **CMCVIROEQAS LAB ID** and **Distribution Number**.

Name of CMCVIROEQAS Coordinator **Signature**

Dr. Rajesh Kannangai

Department of Clinical Virology

Report Dispatch Date: 13-01-2020

Report authorized by: CMCVIROEQAS Coordinator

END OF REPORT

CMCVIROEQAS
(Under the aegis of Indian Association of Medical Microbiologists)
PT Unit, Department of Clinical Virology, Christian Medical College, Vellore-632004, Tamil Nadu
Email: viroeqas@cmcvellore.ac.in Phone: 0416-2283455

8th SEROLOGY CMCVIROEQAS EVALUATION REPORT

PANEL: BBVS

CMCVIROEQAS ID.: V0461 **Result Receiving Date:** 27/7/19

Distribution No: 0219

Specimen #	Intended Result			Your Result		
	HIV	HBsAg	HCV	HIV	HBsAg	HCV
S0121905	Negative	Positive	Negative	NEGATIVE	POSITIVE	NEGATIVE
S0121906	Negative	Negative	Negative	NEGATIVE	NEGATIVE	NEGATIVE
S0121907	Negative	Negative	Negative	NEGATIVE	NEGATIVE	NEGATIVE
S0121908	Negative	Positive	Negative	NEGATIVE	POSITIVE	NEGATIVE
Your Score				**8/8 (100%)**	**8/8 (100%)**	**8/8 (100%)**

Cumulative Report of this cycle:

Total Number of specimens you received : 4

Number of markers reported as not examined : 0

Specimen # not used for analysis : 0

Number of Specimens Reported Late for analysis : 0

Your cumulative score for the specimens you reported: 24 out of the possible total of 24

CMCVIROEQAS
(Under the aegis of Indian Association of Medical Microbiologists)
PT Unit, Department of Clinical Virology, Christian Medical College,
Vellore-632004, Tamil Nadu
Email: viroeqas@cmcvellore.ac.in Phone: 0416-2283455

Total Number of participants for BBVS : 504

Total Number of Participants who turned in their results : 466

Participants who reported all analyzed specimens accurately

Marker	Number of Participants	Percentage of Participants with concordant result for all analyzed specimens
HIV	463	99.8
HBsAg	466	99.1
HCV-Ab	466	99.8

Performance Graph



CMCVIROEQAS
(Under the aegis of Indian Association of Medical Microbiologists)
PT Unit, Department of Clinical Virology, Christian Medical College,
Vellore-632004, Tamil Nadu
Email: viroeqas@cmcvellore.ac.in Phone: 0416-2283455





CMCVIROEQAS
(Under the aegis of Indian Association of Medical Microbiologists)
PT Unit, Department of Clinical Virology, Christian Medical College,
Vellore-632004, Tamil Nadu
Email: viroeqas@cmcvellore.ac.in Phone: 0416-2283455



Comments:

Participants are scored based on qualitative result.

Assigned Value:

Assigned value is determined using multiple assays/multiple testing of the same analyte.

The proficiency testing material is a pooled lyophilized plasma sample prepared by following institutional proficiency testing standard operating protocol (PT-SOP) by trained staff. None of the work related to testing, preparation and packaging of sample is subcontracted. The homogeneity of the PT material is determined using multiple testing of multiple aliquots. The stability of the testing material is determined by assessing the reactivity of the specimen till the closing date.

CMCVIROEQAS
(Under the aegis of Indian Association of Medical Microbiologists)
PT Unit, Department of Clinical Virology, Christian Medical College,
Vellore-632004, Tamil Nadu
Email: viroeqas@cmcvellore.ac.in Phone: 0416-2283455

Scoring System

Qualitative Results	Score
Concordant Result	2
Intermediate/Indeterminate	1
Discordant Result	0

Enquiries: For queries please contact CMCVIROEQAS coordinator at the email **viroeqas@cmcvellore.ac.in**

For all communications please use your **CMCVIROEQAS LAB ID** and **Distribution Number**.

Name of CMCVIROEQAS Coordinator **Signature**

Dr. Rajesh Kannangai

Department of Clinical Virology

Report Dispatch Date: 09-09-2019

Report authorized by: CMCVIROEQAS Coordinator

END OF REPORT

2020: 4th IAMM EQAS Microbiology: Bacteriology/ Serology
Department of Clinical Microbiology, Christian Medical College, Vellore-632004, Tamil Nadu
Email: eqas@cmcvellore.ac.in Phone: 0416-2282588

NABL ACCREDITED ISO / IEC 17043:2010, PC-1033 / 27.12.2018

Member Id: M 0 5 3 2

Last date for receiving reports: July 15, 2020

MARCH 2020 / BACTERIOLOGY SMEARS:

Question: Carry out the appropriate staining procedure and document the relevant observation.
Evaluation format:
Presence and grading of host cells & debris (many/ moderate/few/no) **(1 mark)**
Presence & grading of organism/s gram stain finding, morphology (shape), arrangement and any other special characteristics observed **(2 marks)**
Interpretation: Probable organism OR Impression- as asked in the question **(1 mark)**

Exercise Number	Question	Report	Evaluation
SM1	**Please carry out a Gram stain on the given fixed smear prepared from a voided URINE specimen of a 63 year old diabetic lady with a history of mild dysuria and increased frequency for 2 days.**	**Presence of host cells & debris (1mark):** Pus cells - rare; Epithelial cells - Few **Description of Organism/s (2marks):** Many gram positive cocci in single, pairs & short chains and many gram negative long slender bacilli along with few gram negative cocci in pairs and candida seen. **Impression/comment (1 mark):** Improper collection, "mid stream clean catch" urine sample should be asked for	
SM2	**Please carry out a Gram stain on the given fixed smear prepared from an EXUDATE specimen of a 23 year old man presenting with an exudative lesion on the right leg associated with high grade fever, chills and myalgia for 2 days**	**Presence of host cells & debris (1mark):** Many pus cells. Background filled with debri. **Description of Organism/s (2 marks):** Many gram positive cocci in single pairs and chains seen **Possible organism (1 mark):** Streptococcus pyogenes.	

SM3	**Please carry out a Gram stain on the given fixed smear prepared from an ENDOTRACHEAL ASPIRATE specimen of a 69 year old gentleman admitted in the ICU with worsening saturation.**	**Presence of host cells & debris (1mark):** Many pus cells. Background filled with debris **Description of Organism/s (2 marks):** Many gram negative coccobacilli seen. Few gram negative diplococci seen. **Possible organism (1 mark):** Acinetobacter baumanii along with probably moraxella.	

MARCH 2020 / BACTERIOLOGY CULTURE:

Question: A freeze-dried (lyophilized) culture of an organism isolated from a clinical specimen is given. Carry out the appropriate techniques for each exercise and identify the pathogen. Carry out the antimicrobial susceptibility testing according to the panel given below.

INSTRUCTION: RECONSTITUTION OF LYOPHILIZED CULTURES

The vial containing freeze-dried material must be handled carefully. These vials contain infectious organisms. Please follow standard safety procedures and usual universal precautions when handling this material. It is advised to open the vial in a Bio-safety cabinet Type 2A2

Opening of the lyophilized vial

1. The lyophilized material provided must be rehydrated. When reconstituting them, exercise extreme caution not to create aerosols or spills.
2. Do not mouth pipette.
3. Reconstitute when you are ready to inoculate onto culture plates.
4. Do not remove the whole cap. Lift only the pre-cut section of the metal cap.
5. Disinfect the rubber stopper with 70% alcohol/ rectified spirit.
6. With a sterile needle and syringe pierce the rubber cap and inoculate the rehydrating broth.

Re-hydration and Recovery

1. Add about **0.5ml of Nutrient broth** using a sterile needle and syringe.
2. Gently swirl the vial and allow 5-10 minutes for the dried material to rehydrate completely.
3. Hold the vial vertically.
4. Draw the reconstituted fluid up into the syringe slowly.
5. Separate the needle tip from the syringe carefully.
6. Inoculate the specimen / organism appropriate enriched and/or selective media to facilitate recovery of the organisms.
7. Incubate both vial with remaining contents and plate cultures in the appropriate environment – ambient / CO2 incubator at 35-37°C as per routine procedures.
8. Overnight vial contents can be sub cultured again, if required.
9. After use decontaminate and then discard the vial according to your hospital / lab policy.

Note: The viability and culture purity of all batches of lyophilized cultures have been verified prior to packing. The identification has been confirmed by conventional, automated and molecular methods.

EVALUATION FORMAT:

Culture microscopy& identification: Microscopy (1mark), culture characteristics (2 mark), Biochemical key identification characteristics (2 marks), Final identification (2 marks)
Susceptibility testing: (2 marks per drug)

For culture identifications or susceptibility tests that have been performed by automated systems, the printouts of the automated report MUST be attached along with the report for the evaluator's reference.
✓HOWEVER, THIS REPORT SHEET MUST BE COMPLETED BY YOU.

Susceptibility interpretation errors:
Minor error (mE) : Susceptible / resistant isolate reported as intermediate susceptible (1 mark)
Major error (ME) : Susceptible isolate reported as resistant (0 marks)
Very major error (VME) : Resistant isolate reported as susceptible (-1 marks)

- ✓ **VITEK/ E-test MIC will be awarded the complete mark if the interpretation is consistent with the expected report.**

CU 1: Isolated from a FECES specimen of a 26year old gentleman with a 2 day history of diarrhea and vomiting associated with abdominal pain.

Microscopy Gram stain / motility	Culture characteristics	Biochemical identification MAIN / KEY identification characteristics required for the identification of the organism (Minimum: 3 key characteristics)	Method used in identification: (Please circle which is method has been used)
Gram negative short slim curved comma shaped rods seen. Highly motile	NA: Scanty growth of pale yellow coloured medium sized colonies with mucoid colonies with regular edges seen. BA: Beta haemolytic, moderate growth, large colonies. Mac: Non lactose fermenting	Catalase - Positive Oxidase - Positive Indole - Positive Citrate - Negative. Urease - Positive. TSI - A/A No gas, No H_2S MMM - Mannitol fermented, motile	Manual ✓ Automation Detail:
FINAL Identification of given organism	**Genus**	**Species**	**Serotype (if applicable)**
	Vibrio	cholerae	? O139 (as it is mucoid)

Antibiotics	Ampicillin	Tetracycline	Co-trimoxazole	Cefotaxmine	Ciprofloxacin
Zone size (mm) OR MIC(µg/ml)	20 mm	26 mm	27mm	32 mm	28 mm
Interpretation (S / MS / R)	S	S	S	S	S
Method Details if Automation: (e.g. Vitek – 2, Microscan etc.)					

Please note:

1. **Provide only ONE FINAL susceptibility report for each drug tested. If two reports with discrepant interpretations are reported, they will be marked as an incorrect answer henceforth.**
2. **Incomplete forms will NOT be evaluated henceforth.**

CU 2: Isolated from a URINE specimen of a 35year old gentleman with hemiplegia on a long term urinary catheter

Microscopy Gram stain / motility	Culture characteristics	Biochemical identification MAIN / KEY identification characteristics required for the identification of the organism (Minimum: 3 key characteristics)	Method used in identification: (Please circle which is method has been used)
Short thin gram negative bacilli seen, some look like coccobacilli Motile	NA: Moderate growth of medium sized red colored circular colonies with smooth glistening surface and regular edges seen. BA: Beta haemolytic deep red coloured colonies. MAC: Red coloured lactose fermenting colonies.	Catalase – Positive Oxidase – Negative Indole – Negative Urease – Positive Citrate – Positive TSI – K/A with gas No H_2S MMM – Mannitol fermented, motile	Manual ✓ Automation Detail:
FINAL Identification of given organism	**Genus** Serratia	**Species** marcescens	**Serotype (if applicable)**

Antibiotics	Cefpodoxime	Co-trimoxazole	Amoxicillin-clavulanate	Levofloxacin	Meropenem
Zone size (mm) OR MIC(µg/ml)	29	24	12	30	26
Interpretation (S / MS / R)	S	S	R	S	S
Method Details if Automation: (e.g. Vitek – 2, Microscan etc.)					

Please note:

1. **Provide only ONE FINAL susceptibility report for each drug tested. If two reports with discrepant interpretations are reported, they will be marked as an incorrect answer henceforth.**
2. **Incomplete forms will NOT be evaluated henceforth.**

CU 3: Isolated from an EXUDATE specimen from a 22year old lady with a history of extensive burns to her right forearm.

Microscopy Gram stain / motility	Culture characteristics	Biochemical identification MAIN / KEY identification characteristics required for the identification of the organism (Minimum: 3 key characteristics)	Method used in identification: (Please circle which is method has been used)
Gram positive cocci in single pairs and clusters Non motile	NA: Moderate growth of golden yellow coloured circular medium sized colonies with smooth moist surface and regular edges. BA: Beta haemolytic Mac: No growth.	Catalase - Positive Oxidase - Negative Slide coagulase - Positive Tube coagulase - Positive Mannitol - fermented Urease - Positive,	Manual ✓ Automation Detail:
FINAL Identification of given organism	**Genus** Methicillin Resistant	**Species** Staphylococcus aureus (MRSA)	**Serotype (if applicable)**

Antibiotics	Cefoxitin	Erythromycin	Co-trimoxazole	Clindamycin	Linezolid
Zone size (mm) OR MIC(µg/ml)	0 mm	26 mm	30 mm	28 mm	33 mm
Interpretation (S / MS / R)	R	S	S	S	S
Method Details if Automation: (e.g. Vitek – 2, Microscan etc.)					

Please note:

1. Provide only ONE FINAL susceptibility report for each drug tested. If two reports with discrepant interpretations are reported, they will be marked as an incorrect answer henceforth.
2. Incomplete forms will NOT be evaluated henceforth.

Please indicate the exercises that you have participated in: ☑ Bacteriology smears ☑ Cultures ☐ Serology

Laboratory head name: Dr. Jothi Prasad

Signature / Seal: [signature] Date of dispatch: 14-7-2020.

Dr. JOTHI PRASAD, M.D.,
MICROBIOLOGIST
Reg. No: 79307

MORRIS HATHLAS NAGERCOIL

Member ID: ☐☐☐☐☐

SM 1	SM2	SM3	CU1	CU2	CU3	SE1	SE2	SE3	Marks obtained
4	4	4	17	17	17	2	2	2	Maximum marks

TOTAL MARKS: ☐☐ Evaluator name / Signature_____ Date_____

103rd IAMM EQAS Microbiology: Bacteriology/ Serology
Department of Clinical Microbiology, Christian Medical College, Vellore-632004, Tamil Nadu
Email: eqas@cmcvellore.ac.in Phone: 0416-2282588

NABL ACCREDITED ISO / IEC 17043:2010, PC-1033 / 27.12.2018

OCTOBER 2019

103rd EQAS EVALUATION REPORT

MEMBER ID: M 0 5 3 2

Marks Obtained: 61.5 / 65 (94.6%)

OCTOBER 2019 / BACTERIOLOGY SMEARS:

Question: Carry out the appropriate staining procedure and document the relevant observation.
Provide the Impression or probable organism seen (AS ASKED)
Please refer the attached evaluation format for details on the criteria for evaluation.

PLEASE NOTE: The inaccuracies in the participant report resulting in deduction of marks has been underlined in the expected report.

Exercise Number	Question	Expected Report	Evaluation		
SM1	Please carry out a Gram stain on the given fixed smear prepared from a Pleural fluid specimen of a 74 year old gentleman with a history of high grade fever associated with cough, breathlessness and chest pain for 2 days.	Presence of host cells & debris (1mark): **Many pus cells** Organism (2marks): **Many Gram positive (oval / flame/ lanceolate) shaped cocci in pairs.** Possible organism (1 mark): ***Streptococcus pneumoniae***	0	0.5	1
			1.5	2	2.5
			3	(3.5)	4
SM2	Please carry out a Gram stain on the given fixed smear prepared from a throat swab specimen of a 6 year old girl with history of low grade fever for 3 days associated with sore throat and stridor.	Presence of host cells & debris (1mark): **No pus cells** Organism (2 marks): **Many Gram positive slender, club shaped bacilli arranged in a cuneiform (X and V letter pattern/ Chinese letter) arrangement.** Possible organism (1 mark): **Corynebacterium species (*Corynebacterium diphtheria*)**	0	0.5	1
			1.5	2	2.5
			3	3.5	(4)

SM3	.Please carry out a Ziehl-Neelsen stain on the given fixed smear prepared from a sputum specimen of a 45 year old gentleman with a history of low grade fever and productive cough for 3 weeks. Please provide the report as per the RNTCP grading format.	Organism (2 marks): **Long, slender, acid fast bacilli with a beaded appearance** FINAL REPORT (2 marks): **Acid-fast bacilli seen - Probably *Mycobacterium tuberculosis*** **RNTCP grading: 1+ (Few AFB seen / 100 oil immersion fields)**	**0**	**0.5**	**1**
			1.5	**2**	**2.5**
			3	**3.5**	**4**

OCTOBER 2019 / BACTERIOLOGY CULTURE:

Question: A freeze-dried (lyophilized) culture of an organism isolated from a clinical specimen is given. Carry out the appropriate techniques for each exercise and identify the pathogen. Carry out the antimicrobial susceptibility testing according to the panel given below.

Please refer the attached evaluation format for details on the criteria for evaluation.

A 'partially correct' or 'incorrect' component of the participant report which has resulted in a deduction of marks has been in indicated in the evaluation report below.

CU1: Isolated from a blood culture specimen of a 72 year old gentleman admitted with high grade fever, chills and increasing somnolence for 2 days.

FINAL INDENTIFICATION: *Escherichia coli*

Identification details	Reported	Not reported	Evaluation (7 marks)
Microscopy (Gram stain + Motility)	✓		**0 0.5 (1)**
Salient culture and biochemical findings enabling final identification (Minimum 3 key characteristics)	✓		**1 2 3 (4)**
Final identification	✓		**0 0.5 1 1.5 (2)**

Susceptibility report	EXPECTED REPORT			PARTICIPANT REPORT		MARK	TYPE OF ERROR
	Zone size (mm)	MIC (µg/ml)	Interpretation	Correct	Incorrect	10 marks	Error
Ceftazidime	≤17	≥ 16.0	Resistant	✓		-1 0 1 (2)	mE/ ME/ VME
Cefotaxime	6mm (≤22 R)	≥4.0	Resistant	✓		-1 0 1 (2)	mE/ ME/ VME
Amikacin	≥17	≤16.0	SUSCEPTIBLE	✓		-1 0 1 (2)	mE/ ME/ VME
Ciprofloxacin	6mm (≤21 R)	≥1.0	Resistant	✓		-1 0 1 (2)	mE/ ME/ VME
Meropenem	≥23	≤1.0	SUSCEPTIBLE	✓		-1 0 1 (2)	mE/ ME/ VME

CU2: Isolated from an exudate specimen of a 65 year old diabetic lady who presented casualty with an exudative burn ulcer on her left lower limb. She had been discharged from hospital 8 days ago with healing ulcers and had been advised daily dressings.

FINAL IDENTIFICATION: *Shewanella algae*

Identification details	Reported	Not reported	Evaluation (7 marks)
Microscopy (Gram stain + Motility)	✓		0 0.5 (1)
Salient culture and biochemical findings enabling final identification (Minimum 3 key characteristics)	✓		1 2 3 (4)
Final identification	✓		0 0.5 1 1.5 (2)

Susceptibility report	EXPECTED REPORT			PARTICIPANT REPORT		MARK	TYPE OF ERROR
	Zone size (mm)	MIC (µg/ml)	Interpretation	Correct	Incorrect	8 marks	Error
Ceftazidime	Disk diffusion not recommended as per CLSI-M100 Ed 29 (2019)*	≤8.0	Susceptible	NOT EVALUATED			
Amikacin		≤16.0	Susceptible				
Piperacillin/ Tazobactam		≤16.0/4	Susceptible				
Ciprofloxacin		≥4.0	RESISTANT				
Imipenem		8.0 (BMD)	Intermediate susceptible				

*Disk diffusion reports NOT evaluated.

CU3: Isolated from a urine specimen of a 66 year old gentleman on an indwelling urethral catheter, following trans-urethral resection of the prostate gland.

FINAL IDENTIFICATION: ***Staphylococcus epidermidis***

Identification details	Reported	Not reported	Evaluation (7 marks)
Microscopy (Gram stain + Motility)	✓		0 0.5 (1)
Salient culture and biochemical findings enabling final identification (Minimum 3 key characteristics)	✓		1 2 3 (4)
Final identification	✓	Species Incorrect	0 0.5 (1) 1.5 2

Susceptibility report	EXPECTED REPORT			PARTICIPANT REPORT		MARK	TYPE OF ERROR
	Zone size (mm)	MIC (µg/ml)	Interpretation	Correct	Incorrect	10 marks	Error
Cefoxitin	≥18	Oxacillin ≤0.25	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME
Nitrofurantoin	≥17	≤32.0	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME
Co-trimoxazole	≥16	<2.0/38	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME
Ciprofloxacin	≥21	≤1.0	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME
Linezolid	≥21	≤4.0	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME

OCTOBER 2019 / SEROLOGY

Test method employed for detection C-reactive protein (CRP) at your lab: Turbidimetry
Peer group (n) = 342
Please refer the attached evaluation format for details on the criteria for evaluation

	Parameter	Your Result	Your Value (mg/L)	Intended Result	Robust Mean	Robust SD	Range (mg/L)	Z & Z' score	Max Marks	Your Score
SE1	CRP	Positive	18.8	Positive	7.8969	2.2991	0.43 to 91.0	4.7	2	1
SE2	CRP	Positive	14.4	Positive	9.5119	2.7355	0.58 to 53.9	1.8	2	2
SE3	CRP	Positive	60.1	Positive	41.1027	8.3918	0.1 to 112.4	2.2	2	1.5

OCTOBER 2019 / SEROLOGY

Test method employed for detection Widal at your lab: Tube Agglutination

Please refer the attached evaluation format for details on the criteria for evaluation

Parameter		Your Interpretation		Intended Result					Max Marks	Your Score
		Correct	Incorrect	STO	STH	SPAH	SPBH	Interpretation		
SE1	Widal	√		Negative	Negative	Negative	Negative	Negative	2	2
SE2	Widal	√		Negative	Negative	Negative	Negative	Negative	2	2
SE3	Widal	√		Negative	Negative	Negative	Negative	Negative	2	2

Disclaimer:

This is a confidential document and subject to the rules of confidentiality as described by the ISO 17043:2010 standard.

MEMBER ID: M 0 5 3 2

SM 1	SM2	SM3	CU1	CU2	CU3	SE1	SE2	SE3	Marks obtained	
3.5	4	3.5	17	7	16	3	4	3.5	61.5	94.6%
4	4	4	17	7	17	4	4	4	Maximum marks = 65	

Dr. Rani Diana Sahni
Scientific Co-ordinator

Dr. John A Jude Prakash
Quality Manager

Dr. V. Balaji
PT Co-ordinator

Report Dispatch Date: 15.02.2020

********** End of Report **********

IAMM EQAS Microbiology: Bacteriology/ Serology
Department of Clinical Microbiology, Christian Medical College, Vellore-632004, Tamil Nadu
Email: eqas@cmcvellore.ac.in Phone: 0416-2282588

MICROBIOLOGY EXTERNAL QUALITY ASSESSMENT SCHEME

Under the aegis of Indian Association of Medical Microbiologists

NABL ACCREDITED ISO / IEC 17043:2010, PC-1033 / 27.12.2018

JUNE 2019

102nd EQAS EVALUATION REPORT

MEMBER ID: M 0 5 3 2

Marks Obtained: 74.5 / 77 (96.8%)

JUNE 2019 / BACTERIOLOGY SMEARS:

Question: Carry out the appropriate staining procedure and document the relevant observation.
Provide the Impression or probable organism seen (AS ASKED)
Please refer the attached evaluation format for details on the criteria for evaluation.

PLEASE NOTE: The inaccuracies in the participant report resulting in deduction of marks has been underlined in the expected report.

Exercise Number	Question	Expected Report	Evaluation		
SM1	Please carry out a Gram stain on the given fixed smear prepared from a **BLOOD** culture of a 45year old gentleman with a history of low grade intermittent fever for 3 weeks and worsening breathlessness.	Organism: **Gram positive spherical cocci arranged in pairs, short chains and predominantly long chains. (2)** Impression and probable organism: **Case of PUO- Probable case of infective endocarditis. Probably caused by *Streptococcus* spp - Viridans Streptococcus. (2)**	0	0.5	1
			1.5	2	2.5
			3	3.5	(4)
SM2	Please carry out a Gram stain on the given fixed smear prepared from a **CSF** specimen of a 2 year old child with a history of high grade fever, irritability and vomiting.	Presence of host cells & debris: **Many pus cells (1)** Organism: **Many Gram negative coccobacilli, short slender bacilli and long slender bacilli. [Pleomorphism seen] (2)** Possible organism: **Probably *Hemophilus* species (1)**	0	0.5	1
			1.5	2	2.5
			3	3.5	(4)

SM3	Please carry out a Gram stain on the given fixed smear prepared from an **EXUDATE** specimen of a 21 year old lady with a history of burns to her right forearm.	Presence of host cells & debris: **Many pus cells (1.0).** **[NO epithelial cells]** Organism: **Many Gram negative long, slender bacilli and Gram negative short, plump bacilli seen. (2)** Probable organism/s: **Gram negative bacterial infection.** **Predominant organism probably *Pseudomonas* spp (1)**	**0** **1.5** **3**	**0.5** **2** **3.5**	**1** **2.5** **(4)**

JUNE 2019 / BACTERIOLOGY CULTURE:

Question: A freeze-dried (lyophilized) culture of an organism isolated from a clinical specimen is given. Carry out the appropriate techniques for each exercise and identify the pathogen. Carry out the antimicrobial susceptibility testing according to the panel given below.

Please refer the attached evaluation format for details on the criteria for evaluation.

A 'partially correct' or 'incorrect' component of the participant report which has resulted in a deduction of marks has been in indicated in the evaluation report below.

CU1: Isolated from a sputum specimen of a 55 year old gentleman with a history smoking for the past 30 years and admitted with high grade fever and cough with increasing breathlessness.

FINAL INDENTIFICATION: *Klebsiella pneumoniae* subspp pneumoniae (no marks deducted if subspecies was not mentioned)

Identification details	Reported	Not reported	Evaluation (7 marks)
Microscopy (Gram stain + Motility)	✓		**0 0.5 (1)**
Salient culture and biochemical findings enabling final identification (Minimum 3 key characteristics)	✓		**1 2 3 (4)**
Final identification	✓		**0 0.5 1 1.5 (2)**

Susceptibility report	EXPECTED REPORT			PARTICIPANT REPORT		MARK	TYPE OF ERROR
	Zone size (mm)	MIC (µg/ml)	Interpretation	Correct	Incorrect	12 marks	Error
Cefotaxime	6	≥4.0	Resistant	✓		-1 0 1 (2)	mE/ ME/ VME
Ceftazidime	6	>64.0	Resistant	✓		-1 0 1 (2)	mE/ ME/ VME
Amikacin	6	≥64.0	Resistant	✓		-1 0 1 (2)	mE/ ME/ VME
Piperacillin/ tazobactam	6	≥128/4	Resistant	✓		-1 0 1 (2)	mE/ ME/ VME
Levofloxacin	6	>8.0	Resistant	✓		-1 0 1 (2)	mE/ ME/ VME
Meropenem	6	>32.0	Resistant	✓		-1 0 1 (2)	mE/ ME/ VME

CU2: Isolated from a urine specimen of a 22 year old married woman with a 2 day history of increased urgency, frequency of micturition and dysuria.

FINAL IDENTIFICATION: ***Staphylococcus saprophyticus***

Identification details	Reported	Not reported	Evaluation (7 marks)
Microscopy (Gram stain + Motility)	✓		0 0.5 (1)
Salient culture and biochemical findings enabling final identification (Minimum 3 key characteristics)	✓		1 2 3 (4)
Final identification	✓		0 0.5 1 1.5 (2)

Susceptibility report	EXPECTED REPORT			PARTICIPANT REPORT		MARK	TYPE OF ERROR
	Zone size (mm)	MIC (µg/ml)	Interpretation	Correct	Incorrect	10 marks	Error
Cefoxitin	27	≤4.0	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME
Co-trimoxazole	30	≤2.0	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME
Nitrofurantoin	21	<32.0	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME
Ciprofloxacin	24	≤1.0	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME
Linezolid	30	≤4.0	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME

CU3: Isolated from stool specimen of a 45 year old gentleman with a history of abdominal pain, frequent loose stools and fatigue for 2 days.

FINAL IDENTIFICATION: *Salmonella enterica* subsp *enterica* serovar Typhimurium

Identification details	Reported	Not reported	Evaluation (7 marks)
Microscopy (Gram stain + Motility)	✓		0 0.5 (1)
Salient culture and biochemical findings enabling final identification (Minimum 3 key characteristics)	✓		1 2 3 (4)
Final identification	✓		0 0.5 1 1.5 (2)

Susceptibility report	EXPECTED REPORT			PARTICIPANT REPORT		MARK	TYPE OF ERROR
	Zone size (mm)	MIC (µg/ml)	Interpretation	Correct	Incorrect	10 marks	Error
Ampicillin	24	≤8.0	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME
Chloramphenicol	24	≤8.0	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME
Co-trimoxazole	28	≤2.0 (0.125)	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME
Ceftriaxone	30	≤1.0 (0.047)	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME
Ciprofloxacin	33	≤0.25 (0.015)	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME

JUNE 2019 / SEROLOGY

Test method employed for detection C - reactive protein at your lab: Turbidimetry

Peer group (n) = 339

Please refer the attached evaluation format for details on the criteria for evaluation

	Parameter	Your Result	Your Value (mg/L)	Intended Result	Robust Mean	Robust SD	Range (mg/L)	Z /Z' score	Max Marks	Your Score
SE1	CRP	Positive	7.0	Negative	2.9013	1.2276	0.0 – 43.92	3.3	2	0
SE2	CRP	Negative	5.6	Negative	2.3069	1.2641	0.0 – 50.65	2.6	2	1.5
SE3	CRP	Positive	67.2	Positive	62.1031	14.8079	0.76 - 145	0.3	2	2

Test method employed for detection Antistreptolysin O (ASO) your lab: Turbidimetry

Peer group (n) = 177

Please refer the attached evaluation format for details on the criteria for evaluation

	Parameter	Your Result	Your Value (IU/mL)	Intended Result	Robust Mean	Robust SD	Range (IU/mL)	Z / Z' score	Max Marks	Your Score
SE1	ASO	Negative	83	Negative	94.8569	32.0891	3.87 – 236.9	-0.4	2	2
SE2	ASO	Negative	86	Negative	87.4985	29.2287	0.32 – 254.3	-0.1	2	2
SE3	ASO	Negative	128	Negative	138.059	45.1067	33 – 374.2	-0.3	2	2

Disclaimer:

This is a confidential document and subject to the rules of confidentiality as described by the ISO 17043:2010 standard.

MEMBER ID: M 0 5 3 2

SM 1	SM2	SM3	CUi	CU2	CU3	SE1	SE2	SE3	Marks obtained	
4	4	4	19	17	17	2	3.5	4	74.5	96.8%
4	4	4	19	17	17	4	4	4	Maximum marks = 77	

Dr. Rani Diana Sahni
Scientific Co-ordinator

Dr. John A Jude Prakash
Quality Manager

Dr. V. Balaji
PT Co-ordinator

Report Dispatch Date: 31.10.2019

********** End of Report **********

Result Entry (Pin: 2243) Choose Survey No: 482020

0416-2283618

Download Result (download_result.php?survery_no=482020)

1. PROTHROMBIN TIME RESULTS

Results	Specimen ID 1# 482020 C1	Specimen ID 2# 482020 C2
Prothrombin Time(secs)	18.8	19.2
Prothrombin Ratio	13	13
Interpretation		
I N R	1.50	1.54
Interpretation		

2. ACTIVATED PARTIAL THROMBOPLASTIN TIME RESULTS

Results	Specimen ID1# 482020 C1	Specimen ID2# 482020 C2
APTT (secs)	42	50.9
Interpretation		

3. THROMBIN TIME RESULTS

Results	Specimen ID1# 482020 C1	Specimen ID2# 482020 C2
TT (secs)		

Participant # **2243** **Survey # 482020**

Parameter **Prothrombin Time**

Group All results

Sample #	482020 C1	482020 C2
Your result (secs)	18.80	19.20
Your Assigned Value & LAP	17.30(14.71-19.90)	19.51(16.58-22.43)
Limits of acceptable performance	Assigned value ±15%	Assigned value ±15%
Number of Participants	806	806
Coefficient of Variation CV (%)	14.42	14.31
Your performance	Within consensus	Within consensus





All results (Your result x)



Your interpretation

Over all interpretation (%)

Not assessable	13(2%)	Not assessable	14(2%)
Normal	58(7%)	Normal	18(2%)
Borderlin	91(11%)	Borderlin	70(9%)
Abnormal	77(10%)	Abnormal	135(17%)
Above therapeutic interval	2(0%)	Above therapeutic interval	4(0%)
Within therapeutic interval	2(0%)	Within therapeutic interval	1(0%)
Below therapeutic interval	1(0%)	Below therapeutic interval	1(0%)
		Probable factor deficiency	1(0%)

Survey Open Date: 16-03-2020

Survey Close Date: 18-07-2020

Evelyn 7/8/2020

Participant # **2243** **Survey # 482020**

Parameter **Prothrombin Time INR**

Group All results

Sample #	482020 C1	482020 C2
Your result	1.50	1.54
Your Assigned Value & LAP	1.38(1.17-1.59)	1.59(1.35-1.83)
Limits of acceptable performance	Assigned value ±15%	Assigned value ±15%
Number of Participants	804	804
Coefficient of Variation CV (%)	13.44	13.40
Your performance	Within consensus	Within consensus





All results (Your result x)



Your interpretation

Over all interpretation (%)

Not assessable	10(1%)	Not assessable	12(1%)
Normal	37(5%)	Normal	15(2%)
Borderlin	33(4%)	Borderlin	30(4%)
Abnormal	19(2%)	Abnormal	41(5%)
Above therapeutic interval	29(4%)	Above therapeutic interval	43(5%)
Within therapeutic interval	51(6%)	Within therapeutic interval	40(5%)
Below therapeutic interval	64(8%)	Below therapeutic interval	61(8%)
Probable factor deficiency	1(0%)	Probable factor deficiency	2(0%)

Survey Open Date: 16-03-2020

Survey Close Date: 18-07-2020

TT Control for this test		
TT Ratio		
Interpretation		

4. FIBRINOGEN ASSAY

Result	Specimen ID1# 482020 C1	Specimen ID2# 482020 C2
Fibrinogen Assay (U/dl)		
Interpretation		

5. FACTOR VIII: C ASSAY

Result	Specimen ID1# 482020 C1	Specimen ID2# 482020 C2
Factor VIII (U/dl)		
Interpretation		

6. FACTOR IX: C ASSAY

Result	Specimen ID1# 482020 C1	Specimen ID2# 482020 C2
Factor IX (U/dl)		
Interpretation		

7.VON WILLEBRAND ANTIGEN ASSAY

Result	Specimen ID1# 482020 C1	Specimen ID2# 482020 C2
vW Ag (U/dl)		
Interpretation		

8.VON WILLEBRAND RISTOCETIN COFACTOR ASSAY

Result	Specimen ID1# 482020 C1	Specimen ID2# 482020 C2

Participant # **2243** **Survey # 482020**

Parameter **Activated Partial Thromboplastin Time**

Group	All results	
Sample #	482020 C1	482020 C2
Your result (secs)	42.00	50.90
Your Assigned Value & LAP	45.20(38.42-51.98)	59.20(44.40-74.00)
Limits of acceptable performance	Assigned value ±15%	Assigned value ±25%
Number of Participants	723	721
Coefficient of Variation CV (%)	15.76	18.01
Your performance	Within consensus	Within consensus





All results (Your result x)



Your interpretation

Over all interpretation (%)

Not assessable	12(2%)	Not assessable	13(2%)
Normal	34(5%)	Normal	1(0%)
Borderlin	42(6%)	Borderlin	24(3%)
Abnormal	131(18%)	Abnormal	177(25%)
Above therapeutic interval	3(0%)	Above therapeutic interval	6(1%)
Within therapeutic interval	1(0%)	Probable factor deficiency	1(0%)
Probable factor deficiency	1(0%)	Probable inhibitor	1(0%)

Survey Open Date: 16-03-2020

Survey Close Date: 18-07-2020

vW Ristocetin Assay (U/dl)		
Interpretation		

Survey Received : 2020-03-16
Survey Returned : 2020-04-02

Comments

VIVEK LABORATORIES®

H.O. No 1159 K.P Road, Nagercoil - 629 003, Tamilnadu, INDIA.
e-mail : vivek_laboratories@yahoo.com
website : www.viveklabs.com
91- 4652 - 230108, 230109, 23440
Fax : 91 - 4652 - 221108

Patient ID: P0601433

SID No. : **024546/17**
Name : **Mr. SAHAYAM**
Ref By : **DR.MORRIS MATHIAS HOSPITAL,NAGERKOVIL.**

Age / Sex : **39 Yrs/Male**
IP/OP No : 2260aa
Reg. Date & Time : 11/04/2017 /
Collection Date & Time : 11/04/2017 /
Reported Date & Time : 12/04/2017 /

Specimen : **CLOTTED BLOOD**
Sample Type : **Outside**

WESTERN BLOT TEST FOR HIV

Company Name: J.Mitra Lot.No: HWB051215 Strip.No: 1228

Antigens		Ref Std		Result
HIV - 1				
Polymeric form of gp 41	gp 160	gp160		POSITIVE
Outer Membrane	gp 120	gp120		POSITIVE
Reverse Transcriptase	p 66	P66		NEGATIVE
Precursor Proteins / Reverse Transcriptase	p 55/p 51	P51/55		POSITIVE
Transmembrane	gp 41	gp41		NEGATIVE
Endonuclease	p 31	P31		NEGATIVE
Core Protein	p 24	P24		POSITIVE
Core Protein	p 17	P17		NEGATIVE
HIV - 2	**Control**	CONTROL		PRESENT
Envelope Antigens Specific / Synthetic / Peptide		1211 1212	1228	NEGATIVE

Interpretation

HIV - 1 : POSITIVE

HIV - 2 : NEGATIVE

REPORT RECEIVED BY
S. Sai Kumar
Date: 12/04/2017

---End of Report---

Dr.S.R.SRINIVASA KANNAN.M.D.Path.
DIRECTOR & PATHOLOGIST

LALITHA SRINIVASAN. S,M.Sc,M
MICROBIOLOGIST

P.N: We also do CD4,CD8 Count and PCR.

VIVEK LABORATORIES™

H.O. No 1159 K.P Road, Nagercoil - 629 003, Tamilnadu, INDIA.
Ph: 91- 4652 - 230108, 230109, 234408.Fax: 91 - 4652 - 221108,
e - mail: vivek_laboratories@yahoo.com
www.viveklaboratories.com

Patient ID : P0601433

SID No. : 024546/17
Name : Mr. SAHAYAM
Ref By : DR.MORRIS MATHIAS HOSPITAL,NAGERKOVIL.

Age / Sex :39 Yrs/Male
IP/OP No :2260aa
Reg. Date & Time :11/04/2017 / 22:01
Collection Date & Time :11/04/2017 / 22:01
Reported Date & Time :12/04/2017 / 16:12

Specimen : CLOTTED BLOOD
Sample Type : Outside

Test Report

Test Name	Result	Units	Reference Range
HIV I Ag (P24) & HIV I & II IgG AB(ECLIA)			
Patient's Value	: 223.200		Negative : < 0.90 Borderline : 0.90 - 1.0 positive : > 1.0
Result	: POSITIVE		

---- End of Report ----

Dr.S.R.SRINIVASA KANNAN.M.D.Path.
DIRECTOR & PATHOLOGIST

LALITHA SRINIVASAN. S,M.Sc,Mphil.,
MICROBIOLOGIST

REPORT RECEIVED BY
S.Sai Kumar
Date: 12/04/2017

VIVEK LABORATORIES®

H.O. No 1159 K.P Road, Nagercoil - 629 003, Tamilnadu, INDIA.
Ph: 91- 4652 - 230108, 230109, 234408. Fax: 91 - 4652 - 221108,
e - mail: vivek_laboratories@yahoo.com
www.viveklaboratories.com

SID No. : 051480/17
Name : Mr. PRABHU
Ref By : DR.MORRIS MATHIAS HOSPITAL,NAGERKOVIL.

Patient ID : P0627545

Age / Sex :38 Yrs/Male
IP/OP No :NA
Reg. Date & Time :22/07/2017 / 14:
Collection Date & Time :22/07/2017 / 14:
Reported Date & Time :22/07/2017 / 16:

Specimen : CLOTTED BLOOD
Sample Type : Outside

Test Report

Test Name	Result	Units	Reference Range
HIV I Ag (P24) & HIV I & II IgG AB(ECLIA)			
Patient's Value	: 1963.000		Negative : < 0.90 Borderline : 0.90 - 1.0 positive : > 1.0
Result	: POSITIVE		

P.N: ECLIA Positive result should be correlated clinically and if necessary confirmed by repeat testing or by WESTERN BLOT METHOD.

---- End of Report ----

Dr.S.R.SRINIVASA KANNAN.M.D.Path.
DIRECTOR & PATHOLOGIST

VIGILA CHRISTY. R, M.Sc M.Phil.,
MICROBIOLOGIST

Hemo
24/7/17

REPORT RECEIVED BY:
Prabhu
Date : 24/7/17

VIVEK LABORATORIES®

No.253, K/1,(1159) K.P. Road, Nagercoil - 629 003, Tamilnadu, INDIA.
Ph : 91-4652-230108, 230109, 234408. Fax:91-4652-221108,
Mobile : 97877 20091, 97877 30063
e-mail : vivek_laboratories@yahoo.com
www.viveklaboratories.com

Branch : **NAGERCOIL**
SID No. : **01087529 / 18**
Name : **Mr. JOHNSON**
Ref By : DR.MORRIS MATHIAS HOSPITAL,NAGERKOVIL.

Patient ID :0100076490

Age / Sex : **48 Yrs / Male**
IP / OP No : NA
Reg.Date & Time : 18/12/2018 00
Coll Date & Time : 17/12/2018 23
Reported Date & Time : 18/12/2018 17

WESTERN BLOT TEST FOR HIV

Company Name : J.mitra Lot.No: HWB010118 Strip.No: 0725

Antigens		Ref Std	Test	Result
HIV - 1				
Polymetric form of gp 41	gp 160			NEGATIVE
Outer Membrane	gp 120			NEGATIVE
Reverse Transcriptase	p 66			NEGATIVE
Precursor Proteins / Reverse Transcriptase	p 55/ p 51			NEGATIVE
Transmembrane	gp 41			NEGATIVE
Endonuclease	p 31			POSITIVE
Core Protein	p 24			POSITIVE
Core Protein	p 17			NEGATIVE
HIV - 2	**Control**	1356	0725	PRESENT
Envelope Antigens Specific / Synthetic / Peptide				NEGATIVE

Interpretation

HIV - 1 INDETERMINATE

HIV - 2 NEGATIVE

Comment: Repeat the HIV Western blot test after three months or do PCR.

--- End of Report ---

REPORT RECEIVED BY:
S. Sai Kumar
Date : 18/12/2018

Dr.S.R.SRINIVASA KANNAN.M.D.Path
DIRECTOR & PATHOLOGIST

Report received and entered in notes
By: Shibi
Date 18.12.18

VIGILA CHRISTY. R, M.Sc M.Phil.,
MICROBIOLOGIST